TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast
Brief Summary: To assess the role of interstitial brachytherapy alone compared to whole breast irradiation in a defined low-risk group of invasive breast cancer or ductal carcinoma in situ concerning local failure (all ipsilateral local recurrences) to affirm the hypothesis that local control rates in each arm are equivalent.


Options:
A: Arm Label: Intra-operative radiotherapy; Type: EXPERIMENTAL; Interventions: Device: Intrabeam | Arm Label: Post-operative radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Post-operative radiotherapy | Intervention Type: DEVICE; Name: Intrabeam; Assigned to Arm(s): Intra-operative radiotherapy | Intervention Type: RADIATION; Name: Post-operative radiotherapy; Assigned to Arm(s): Post-operative radiotherapy
B: Arm Label: Whole breast irradiation (WBI); Type: ACTIVE_COMPARATOR; Interventions: Radiation: Whole breast irradiation (WBI) | Arm Label: Partial breast irradiation (APBI); Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation (APBI); Assigned to Arm(s): Partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Whole breast irradiation (WBI); Assigned to Arm(s): Whole breast irradiation (WBI)
C: Arm Label: ELIOT; Type: EXPERIMENTAL; Interventions: Radiation: intraoperative radiotherapy | Arm Label: EXTERNAL RT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: external fractionated radiotherapy | Intervention Type: RADIATION; Name: external fractionated radiotherapy; Assigned to Arm(s): EXTERNAL RT | Intervention Type: RADIATION; Name: intraoperative radiotherapy; Assigned to Arm(s): ELIOT
D: Arm Label: APBI; Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation | Arm Label: EBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: External beam whole breast irradiation | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation; Assigned to Arm(s): APBI | Intervention Type: RADIATION; Name: External beam whole breast irradiation; Assigned to Arm(s): EBRT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast
Brief Summary: To assess the role of interstitial brachytherapy alone compared to whole breast irradiation in a defined low-risk group of invasive breast cancer or ductal carcinoma in situ concerning local failure (all ipsilateral local recurrences) to affirm the hypothesis that local control rates in each arm are equivalent.


Options:
A: Arm Label: Intra-operative radiotherapy; Type: EXPERIMENTAL; Interventions: Device: Intrabeam | Arm Label: Post-operative radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Post-operative radiotherapy | Intervention Type: DEVICE; Name: Intrabeam; Assigned to Arm(s): Intra-operative radiotherapy | Intervention Type: RADIATION; Name: Post-operative radiotherapy; Assigned to Arm(s): Post-operative radiotherapy
B: Arm Label: APBI; Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation | Arm Label: EBRT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: External beam whole breast irradiation | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation; Assigned to Arm(s): APBI | Intervention Type: RADIATION; Name: External beam whole breast irradiation; Assigned to Arm(s): EBRT
C: Arm Label: Standard or Hypofractionated radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Whole Breast Irradiation + Boost or Hypofractionated irradiation | Arm Label: Accelerated Partial Breast Irradiation (APBI); Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation | Intervention Type: RADIATION; Name: Whole Breast Irradiation + Boost or Hypofractionated irradiation; Assigned to Arm(s): Standard or Hypofractionated radiotherapy | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation; Assigned to Arm(s): Accelerated Partial Breast Irradiation (APBI)
D: Arm Label: Whole breast irradiation (WBI); Type: ACTIVE_COMPARATOR; Interventions: Radiation: Whole breast irradiation (WBI) | Arm Label: Partial breast irradiation (APBI); Type: EXPERIMENTAL; Interventions: Radiation: Accelerated partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Accelerated partial breast irradiation (APBI); Assigned to Arm(s): Partial breast irradiation (APBI) | Intervention Type: RADIATION; Name: Whole breast irradiation (WBI); Assigned to Arm(s): Whole breast irradiation (WBI)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes
Brief Summary: The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent acute coronary syndrome (ACS) and to assess the ability of rivaroxaban to reduce the occurrence of death, myocardial infarction (heart attack), repeat myocardial infarctions, stroke, and ischemia (inadequate blood supply to a local area) in patients with recent ACS.


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban/Placebo | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban/Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): 001
D: Arm Label: Warfarin/placebo edoxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin tablets, Drug: placebo edoxaban | Arm Label: high dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (high dose regimen-60mg), Drug: placebo warfarin | Arm Label: low dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (low dose regimen-30mg), Drug: placebo warfarin | Intervention Type: DRUG; Name: warfarin tablets; Assigned to Arm(s): Warfarin/placebo edoxaban | Intervention Type: DRUG; Name: Edoxaban tablets (high dose regimen-60mg); Assigned to Arm(s): high dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: Edoxaban tablets (low dose regimen-30mg); Assigned to Arm(s): low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo warfarin; Assigned to Arm(s): high dose edoxaban/placebo warfarin, low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo edoxaban; Assigned to Arm(s): Warfarin/placebo edoxaban

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coronary Syndromes
Brief Summary: The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent acute coronary syndrome (ACS) and to assess the ability of rivaroxaban to reduce the occurrence of death, myocardial infarction (heart attack), repeat myocardial infarctions, stroke, and ischemia (inadequate blood supply to a local area) in patients with recent ACS.


Options:
A: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban/Placebo | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban/Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): 001
C: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Leipzig Immediate Versus Early and Late PercutaneouS Coronary Intervention triAl in NSTEMI - LIPSIA-NSTEMI TRIAL
Brief Summary: In non-ST-elevation the optimal time of percutaneous coronary intervention (PCI) is unclear.

Some studies showed benefit of very early PCI, some others early PCI between 12-48 hours and others even showed a benefit of a selective invasive approach only in case of recurrence of symptoms or a positive stress test.

The optimal timing of intervention is still matter of debate as a result of a randomized clinical trial.


Options:
A: Arm Label: Radial; Type: EXPERIMENTAL; Interventions: Procedure: Radial approach | Arm Label: Femoral; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Femoral approach | Intervention Type: PROCEDURE; Name: Femoral approach; Assigned to Arm(s): Femoral | Intervention Type: PROCEDURE; Name: Radial approach; Assigned to Arm(s): Radial
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: systematic coronary intervention | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Other: coronary intervention only for cases refractory to medical therapy | Intervention Type: OTHER; Name: systematic coronary intervention; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: coronary intervention only for cases refractory to medical therapy; Assigned to Arm(s): 2
C: Arm Label: Immediate Intervention; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Timing of percutaneous coronary intervention | Arm Label: Early Intervention; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Timing of percutaneous coronary intervention | Arm Label: Selective invasive angiography; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Timing of percutaneous coronary intervention | Intervention Type: PROCEDURE; Name: Timing of percutaneous coronary intervention; Assigned to Arm(s): Early Intervention, Immediate Intervention, Selective invasive angiography
D: Arm Label: Eptifibatide; Type: EXPERIMENTAL; Interventions: Drug: Eptifibatide (Integrilin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eptifibatide (Integrilin); Assigned to Arm(s): Eptifibatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double Dummy, Double Blind, Multinational, Multicenter Trial Comparing the Safety and Efficacy of Sequential (Intravenous/Oral) Moxifloxacin 400 mg OD to Intravenous Piperacillin/Tazobactam 4.0/0.5 g Every 8 Hours Followed by Oral Amoxicillin/Clavulanic Acid Tablets 875/125 mg Every 12 Hours for the Treatment of Subjects With Complicated Skin and Skin Structure Infections
Brief Summary: Patients, who are considered suitable by their physicians to take part in this research, will have a physical examination (including an Electrocardiogram (ECG)), blood and urine samples taken, as well as a sample of the secretions or tissue around their infection site. In addition, the site of the infection will be photographed. The patients will be randomly assigned one of the treatments: intravenous (IV)/per oral (PO) moxifloxacin (drug under evaluation) or IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid (i.e., one of the reference treatments for this kind of infection). The maximum treatment duration will be 21 days, and the minimum will be 7 days. During the hospitalization, the patients will have a physical examination every day. On Day 3-5 during therapy as well as at the end of treatment, the patients will have repeated examinations. These tests and evaluations will be repeated 14 to 28 days after the end of treatment. During this visit, blood and urine samples will be taken only if judged necessary by the physicians.


Options:
A: Intervention Type: DRUG; Name: MK0826, ertapenem sodium / Duration of Treatment - 24 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks; Assigned to Arm(s): N/A
B: Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo group | Arm Label: antibiotic group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-sulfamethoxazole | Intervention Type: DRUG; Name: Trimethoprim-sulfamethoxazole; Assigned to Arm(s): antibiotic group | Intervention Type: DRUG; Name: Placebo group; Assigned to Arm(s): placebo group
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tigecycline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: ampicillin-sulbactam | Intervention Type: DRUG; Name: Tigecycline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ampicillin-sulbactam; Assigned to Arm(s): 2
D: Arm Label: Moxifloxacin; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039) | Arm Label: PIP/TAZ-AMC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid | Intervention Type: DRUG; Name: Moxifloxacin (Avelox, BAY12-8039); Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid; Assigned to Arm(s): PIP/TAZ-AMC

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Advanced Parenting Education in Pediatrics: The APEP Project
Brief Summary: This study will evaluate the effectiveness of a parent training program in improving parenting skills and reducing behavioral symptoms in young children who are at risk for developing childhood behavior disorders.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Incredible Years Program | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Incredible Years Program | Intervention Type: BEHAVIORAL; Name: Incredible Years Program; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Parenting group | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Parenting group; Assigned to Arm(s): 1
C: Arm Label: Intervention Chicago Parent Program arm; Type: EXPERIMENTAL; Interventions: Behavioral: Chicago Parent Program | Arm Label: Parent-Child Interaction Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Parent-Child Interaction Therapy | Intervention Type: BEHAVIORAL; Name: Chicago Parent Program; Assigned to Arm(s): Intervention Chicago Parent Program arm | Intervention Type: BEHAVIORAL; Name: Parent-Child Interaction Therapy; Assigned to Arm(s): Parent-Child Interaction Therapy
D: Arm Label: Family Startup; Type: EXPERIMENTAL; Interventions: Other: Family Startup (in Danish: Familieiværksætterne) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Family Startup (in Danish: Familieiværksætterne); Assigned to Arm(s): Family Startup

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet Intervention to Improve Rural Diabetes Care
Brief Summary: Rural Diabetes Online Care (RDOC) will develop an Internet-based intervention for rural primary care physicians, focusing on improving care for adult patients with diabetes. The intervention, drawing upon the principles of quality improvement and providing tools for system-based changes in practice, is designed for the rural practice, where resources are constrained.


Options:
A: Arm Label: Immediate Treatment Group; Type: EXPERIMENTAL; Interventions: Device: BlueStar app | Arm Label: Delayed Treatment Group; Type: OTHER; Interventions: Device: BlueStar app | Intervention Type: DEVICE; Name: BlueStar app; Assigned to Arm(s): Delayed Treatment Group, Immediate Treatment Group
B: Arm Label: Intervention; Type: OTHER; Interventions: Behavioral: Vascular Management Program, Behavioral: Clinical Care Coordinators, Behavioral: Web-based Vascular Tracker for Patient and Physician, Behavioral: Automated Telephone Reminder System | Intervention Type: BEHAVIORAL; Name: Vascular Management Program; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Clinical Care Coordinators; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Web-based Vascular Tracker for Patient and Physician; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Automated Telephone Reminder System; Assigned to Arm(s): Intervention
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Internet Intervention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Internet Intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
D: Intervention Type: BEHAVIORAL; Name: Telephonic diabetes care; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Comparative, Open-label, Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Mefloquine (250mg) Plus Artesunate (100mg) in Children & Adult Patients With Acute Falciparum Malaria
Brief Summary: The primary objective of this phase III clinical study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of the combination of mefloquine plus artesunate (MQ + AS) in children and adults with uncomplicated P falciparum malaria in South East Asia, India and Africa.


Options:
A: Arm Label: Group A (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group B (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group C (Tablets); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Arm Label: Group D (Granules); Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-Artesunate | Intervention Type: DRUG; Name: Pyronaridine-Artesunate; Assigned to Arm(s): Group A (Tablets), Group B (Tablets), Group C (Tablets), Group D (Granules)
B: Arm Label: Pyronaridine-artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine-artesunate | Arm Label: Artemether-lumefantrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artemether-lumefantrine combination | Intervention Type: DRUG; Name: Pyronaridine-artesunate; Assigned to Arm(s): Pyronaridine-artesunate | Intervention Type: DRUG; Name: Artemether-lumefantrine combination; Assigned to Arm(s): Artemether-lumefantrine
C: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: Artesunate | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate + Mefloquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Artesunate + Mefloquine; Assigned to Arm(s): arm 2
D: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Comparative, Open-label, Randomised, Multi-centre Study to Assess the Efficacy of Pyronaridine Artesunate (180:60mg) Versus Mefloquine (250mg) Plus Artesunate (100mg) in Children & Adult Patients With Acute Falciparum Malaria
Brief Summary: The primary objective of this phase III clinical study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of the combination of mefloquine plus artesunate (MQ + AS) in children and adults with uncomplicated P falciparum malaria in South East Asia, India and Africa.


Options:
A: Arm Label: arm 1; Type: EXPERIMENTAL; Interventions: Drug: Artesunate | Arm Label: arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Artesunate + Mefloquine | Intervention Type: DRUG; Name: Artesunate; Assigned to Arm(s): arm 1 | Intervention Type: DRUG; Name: Artesunate + Mefloquine; Assigned to Arm(s): arm 2
B: Arm Label: PA group; Type: EXPERIMENTAL; Interventions: Drug: pyronaridine artesunate | Arm Label: AL group; Type: ACTIVE_COMPARATOR; Interventions: Drug: arthemeter lumefantrine | Intervention Type: DRUG; Name: pyronaridine artesunate; Assigned to Arm(s): PA group | Intervention Type: DRUG; Name: arthemeter lumefantrine; Assigned to Arm(s): AL group
C: Arm Label: pyronaridine artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine artesunate | Arm Label: chloroquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Intervention Type: DRUG; Name: Pyronaridine artesunate; Assigned to Arm(s): pyronaridine artesunate | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): chloroquine
D: Arm Label: Pyronaridine - artesunate; Type: EXPERIMENTAL; Interventions: Drug: Pyronaridine - artesunate | Arm Label: Mefloquine plus artesunate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine plus artesunate | Intervention Type: DRUG; Name: Pyronaridine - artesunate; Assigned to Arm(s): Pyronaridine - artesunate | Intervention Type: DRUG; Name: Mefloquine plus artesunate; Assigned to Arm(s): Mefloquine plus artesunate

Answer: D